Literature DB >> 19194878

Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden.

Alexander Kellner1, Jakob Matschke, Christian Bernreuther, Holger Moch, Isidro Ferrer, Markus Glatzel.   

Abstract

OBJECTIVE: Active or passive immunization of Alzheimer's disease (AD) patients leads to targeting of beta-amyloid plaques by immunoglobulins (IgG) and their subsequent removal by microglia. Here, we investigate whether naturally occurring autoantibodies to beta-amyloid contribute to beta-amyloid plaque removal in nonimmunized AD patients.
METHODS: We generated an AD tissue microarray with 2,325 tissue specimens from 3 defined central nervous system regions of 48 AD patients and 48 age-matched control patients. Absolute quantification of beta-amyloid, beta-amyloid plaque-bound IgG, and phagocytic, resting, and activated microglia and microhemorrhages was done using a standardized, highly reproducible scoring system.
RESULTS: The majority of neuritic plaques are decorated by IgG. AD patients with prominently IgG-labeled neuritic plaques have a significantly reduced plaque burden and an increase in phagocytic microglia, yet no increase in microhemorrhages.
INTERPRETATION: Autoantibodies directed against beta-amyloid are common in AD patients and may contribute in controlling plaque burden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194878     DOI: 10.1002/ana.21475

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  38 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 2.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

3.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

4.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

5.  Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.

Authors:  Carsten Friedrich; André O von Bueren; Larissa Kolevatova; Christian Bernreuther; Tobias Grob; Diego Sepulveda-Falla; Leander van den Boom; Manfred Westphal; Ronald Simon; Markus Glatzel
Journal:  Childs Nerv Syst       Date:  2015-12-21       Impact factor: 1.475

Review 6.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

Review 7.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 8.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

Review 9.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.